p16INK4a peptide

p16INK4a peptide is a synthetic peptide derived from the tumor suppressor protein p16INK4a (also known as CDKN2A), designed to mimic its activity or act as a vaccine antigen. p16INK4a naturally inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), preventing RB phosphorylation and cell cycle progression from G1 to S phase. In therapeutic contexts, p16INK4a peptides have been used as: - **Direct antitumor agents:** Delivered intracellularly (often via transporter peptides), they can suppress tumor growth and induce G1 cell cycle arrest and apoptosis, as demonstrated in preclinical models of neuroblastoma, B-cell lymphoma, bladder cancer, and gliomas[1][4]. - **Vaccine candidates:** A specific p16INK4a peptide (P16_37-63) has been formulated as a peptide vaccine for patients with advanced HPV-associated, p16INK4a-overexpressing cancers. The vaccine, often administered with adjuvant Montanide ISA-51 VG, aims to induce immune responses (CD4/CD8 T cells and antibodies) against the p16INK4a antigen[2][5]. Development for human therapy is ongoing: clinical studies have confirmed immunogenicity and safety for vaccine use, with most patients experiencing stable disease but no unexpected or dose-limiting toxicities[2][5]. As an antitumor peptide agent, preclinical animal studies support its potential but emphasize the need for improved delivery/combination strategies[1][4].

Other names

P16_37-63 peptidep16(INK4a) peptidep16(INK4A) antitumor peptidep16 peptidep-16 peptidep 16 peptide